Embracing the New Era in Reducing CVD Residual Risk Beyond Statin Therapy

A healthcare gap continues to exist in reducing residual cardiovascular (CV) disease risk among patients with diabetes. To learn more, click below!
A healthcare gap continues to exist in reducing residual cardiovascular (CV) disease risk among patients with diabetes. To learn more, click below!
Enroll in this meeting
April 24, 2019
06:00 PM - 08:15 PM PDT
JW Marriott Los Angeles
900 W. Olympic Boulevard, Los Angeles, California, United States
JW Marriott Los Angeles
Enrollment Fee: Free
  • Overview

    This innovative CME symposium will look at the complex interrelationships of cardiovascular (CV) disease risk as a combination of non-HDL-C, including triglyceride-rich lipoproteins, inflammatory components, glucose-based pathways, and other mechanisms associated with CV disease and its dreaded outcomes.

  • Agenda

    6:00 pm–6:30 pm             

    Registration & Buffet Dinner



    6:30 pm–6:40 pm

    Program Overview



    6:40 pm–7:00 pm

    REDUCE-IT and Other Omega-3 Trials



    7:00 pm–7:20 pm

    Biologic Basis for EPA Modulation in Reducing ASCVD Events Seen in REDUCE-IT



    7:20 pm–7:40 pm

    A New Era in CVD Risk Reduction with Glucose- and Lipid-lowering Agents



    7:40 pm–8:00 pm

    Clinician Live Discussion



    8:00 pm–8:10 pm

    Challenging Cases for Discussion



    8:10 pm-8:15 pm

    Final Comments

    8:15 pm



  • Learning Objectives

    After completing this activity, participants should be better able to:

    • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that reduce ASCVD events beyond statin therapy in patients with diabetes
    • Describe the potential biologic basis for the reductions in ASCVD events observed in REDUCE-IT
    • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches for managing patients with diabetes who have ASCVD or are at high risk of ASCVD events
  • Target Audience

    Endocrinologists, lipidologists, internists, NPs/PAs, diabetes educators, nurses, and other healthcare providers who care for patients with type 2 diabetes, and patients with dyslipidemia.

  • Accreditation and Credit Designation

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and Medtelligence. TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The information provided at this activity is for continuing education purposes only and is not meant to substitute the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free